Analysis of serum HE4 levels in various histologic subtypes of epithelial ovarian cancer and other malignant tumors
Open Access
- 21 December 2021
- journal article
- Published by IOS Press in Tumor Biology
- Vol. 43 (1), 355-365
- https://doi.org/10.3233/tub-211546
Abstract
BACKGROUND: The measurement of serum HE4 levels has emerged as a sensitive and specific biomarker for epithelial ovarian cancers (EOCs). However, serum levels in women diagnosed with various histologic subtypes of EOC and in women with metastatic non-ovarian primary malignancies have not been widely reported. OBJECTIVE: The goal of this study was to identify how serum HE4 levels vary in women diagnosed with different histologic subtypes of EOC and non-ovarian malignancies. METHODS: Data from six prospective pelvic mass clinical trials was combined and an evaluation of serum HE4 levels in women diagnosed with a malignancy was performed. For all patients, serum was obtained prior to surgery and final pathology, including primary tumor site, histologic subtype, grade and stage, were recorded. The mean, median, standard deviation, maximum, and minimum HE4 levels were determined for each group. RESULTS: A total of 984 patients were included in this study, with the average patient age being 60 years old. There were 230 premenopausal and 754 postmenopausal patients. Serum HE4 levels were elevated (≥70.0 pMol) in 85%of EOCs, 40%of LMP tumors, 21%of non-EOCs (germ cell tumors), 25%of cervical cancers, and 47%of non-gynecologic metastatic cancers. Analysis of histologic subtypes revealed 90%(n = 391) of serous, 85%(n = 73) of endometrioid, 45%(n = 42) of mucinous, 86%(n = 51) of mixed tumors, and 69%(n = 36) of clear cell tumors had elevated serum HE4 levels. CONCLUSIONS: Serum HE4 levels are most often elevated in women with high grade serous and endometrioid EOCs, and though serum elevations are seen more often with advanced stage disease, HE4 is also often elevated in early stage disease and lower grade tumors.Keywords
This publication has 27 references indexed in Scilit:
- High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancerJournal of Ovarian Research, 2012
- Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motilityBiochemical and Biophysical Research Communications, 2012
- Prognostic significance of human epididymis protein 4 in epithelial ovarian cancerEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2011
- HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseasesTumor Biology, 2011
- Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic massAmerican Journal of Obstetrics and Gynecology, 2010
- The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying TheoryThe American Journal of Surgical Pathology, 2010
- Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literatureInternational Journal of Gynecologic Cancer, 2007
- Comprehensive analysis of HE4 expression in normal and malignant human tissuesLaboratory Investigation, 2006
- Human Epididymis Protein 4 (HE4) Is a Secreted Glycoprotein that Is Overexpressed by Serous and Endometrioid Ovarian CarcinomasCancer Research, 2005
- Selection of Potential Markers for Epithelial Ovarian Cancer with Gene Expression Arrays and Recursive Descent Partition AnalysisClinical Cancer Research, 2004